Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2024 Earnings Call Transcript August 12, 2024 4:30 PM ET

Company Participants

MarDee Haring-Layton - CAO
Sabrina Martucci Johnson - President and CEO

Conference Call Participants

Catherine Novack - Jones Research
Douglas Tsao - H.C. Wainwright & Co.

Operator

Welcome to the conference call hosted by Daré Bioscience to review the company's second quarter financial results and to provide a general business update. This call is being recorded. My name is Leonardo, and I will be your operator today. With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer; and MarDee Haring-Layton, Chief Accounting Officer. Ms. Haring-Layton, please proceed.

MarDee Haring-Layton

Good afternoon, and welcome to the Daré Bioscience financial results and business update call for the quarter ended June 30, 2024. Today, we will review our second quarter results and discuss developments and expectations for our pipeline and portfolio.

I'd like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including on Form 10-Q for the quarter ended June 30, 2024, which was filed today. I would also like to point out that the content of this call includes time-sensitive information that is current as of today, August 12, 2024. Daré undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law.

I will now turn it over to Sabrina.

Sabrina Martucci Johnson

Thank you. I always like to start our quarterly calls by taking a minute to remind those of you who may be newer to the Daré story of our purpose and our mission. We believe Daré is the only publicly traded company focused solely on women's health, pharmaceutical product development broadly and we remain dedicated to advancing disruptive products for the health and well-being of women through clinical development, regulatory review and ultimately to market. Our commitment and focus is to improve health outcomes and the lives of women by leveraging the basic science and pharmacology that is understood about certain active pharmaceutical ingredients or marketed products to accelerate innovative treatments that women want and need by boldly addressing existing therapeutic gaps. We seek to optimize these treatments for our target indications to enhance outcomes, convenience and side effect profile or to address a novel indication, where the pharmacology is well suited, but has not previously been applied to the indication in question for women. We believe we have the broadest portfolio of potential high-impact first-in-category product candidates to improve the health and wellbeing of women, many of which have already demonstrated proof-of-concept and that our robust pipeline positions us well for the short, medium and long term.